FAKTOR-OPTIONSSCHEIN - GILEAD SCIENCES | Real-time Bid/Ask 09:38:25 2024-06-26 EDT | ||
| 1.65 EUR / 1.66 EUR | -0.90% |
|
| Current month | +40.34% | ||
| 1 month | +26.52% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
Latest news about GILEAD SCIENCES, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-06-26 | 1.6 | -4.19% |
| 24-06-25 | 1.67 | -7.22% |
| 24-06-24 | 1.8 | +3.45% |
| 24-06-21 | 1.74 | +12.26% |
| 24-06-20 | 1.55 | +38.39% |
Delayed Quote Börse Stuttgart
Last update June 26, 2024 at 06:58 am
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | Morgan Stanley |
| WKN | MC2VP6 |
| ISIN | DE000MC2VP67 |
| Date issued | 2019-07-25 |
| Strike | 52.22 $ |
| Maturity | Unlimited |
| Parity | 9.91 : 1 |
| Emission price | 10 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 18 € |
|---|---|
| Lowest since issue | 1.11 € |
| Spread | 0.01 € |
| Spread % | 0.61% |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
69.61
USD
Average target price
82.97
USD
Spread / Average Target
+19.19%
- Stock Market
- Certificates
- Certificat
